新学術領域研究（研究領域提案型） 脳タンパク質老化と認知症制御

国際活動支援班はこちら

ENGLISH

ホーム > 業績 > 論文 A01

論文 A01

A01-1

  1. Ishigaki, S., Fujioka, Y., Okada, Y., Riku, Y., Udagawa, T., Honda, D., Yokoi, S., Endo, K., Ikenaka, K., Takagi, S., Iguchi, Y., Sahara, N., Takashima, A., Okano, H., Yoshida, M., Warita, H., Aoki, M., Watanabe, H., Okado, H., Katsuno, M., and Sobue, G. (2017). Altered Tau Isoform Ratio Caused by Loss of FUS and SFPQ Function Leads to FTLD-like Phenotypes.Cell Rep 18, 1118-1131.
  2. Noda, T., Iijima, M., Noda, S., Maeshima, S., Nakanishi, H., Kimura, S., Koike, H., Ishigaki, S., Iguchi, Y., Katsuno, M., and Sobue, G. (2016). Gene expression profile of inflammatory myopathy with malignancy is similar to that of dermatomyositis rather than polymyositis.Intern Med 55, 2571-2580.
  3. Masuda, M., Senda, J., Watanabe, H., Epifanio, B., Tanaka, Y., Imai, K., Riku, Y., Li, Y., Nakamura, R., Ito, M., Ishigaki, S., Atsuta, N., Koike, H., Katsuno, M., Hattori, N., Naganawa, S., and Sobue, G. (2016). Involvement of the caudate nucleus head and its networks in sporadic amyotrophic lateral sclerosis-frontotemporal dementia continuum.Amyotroph Lateral Scler Frontotemporal Degener 17, 571-579.
  4. Sone J, Mori K, Inagaki T, Katsumata R, Takagi S, Yokoi S, Araki K, Kato T, Nakamura T, Koike H, Takashima H, Hashiguchi A, Kohno Y, Kurashige T, Kuriyama M, Takiyama Y, Tsuchiya M, Kitagawa N, Kawamoto M, Yoshimura H, Suto Y, Nakayasu H, Uehara N, Sugiyama H, Takahashi M, Kokubun N, Konno T, Katsuno M, Tanaka F, Iwasaki Y, Yoshida M, Sobue G. Clinicopathological features of adult-onset neuronal intranuclear inclusion disease.Brain. 2016 Dec;139(Pt 12):3170-3186.
  5. Iguchi Y, Eid L, Parent M, Soucy G, Bareil C, Riku Y, Kawai K, Takagi S, Yoshida M, Katsuno M, Sobue G, Julien JP. Exosome secretion is a key pathway for clearance of pathological TDP-43.Brain. 2016 Dec;139(Pt 12):3187-3201.
  6. Hijikata Y, Katsuno M, Suzuki K, Hashizume A, Araki A, Yamada S, Inagaki T, Iida M, Noda S, Nakanishi H, Banno H, Mano T, Hirakawa A, Adachi H, Watanabe H, Yamamoto M, Sobue G. Impaired muscle uptake of creatine in spinal and bulbar muscular atrophy.Ann Clin Transl Neurol. 2016 Jun 23;3(7):537-46.
  7. Shahrizaila N, Sobue G, Kuwabara S, Kim SH, Birks C, Fan DS, Bae JS, Hu CJ, Gourie-Devi M, Noto Y, Shibuya K, Goh KJ, Kaji R, Tsai CP, Cui L, Talman P, Henderson RD, Vucic S, Kiernan MC. Amyotrophic lateral sclerosis and motor neuron syndromes in Asia.Neurol Neurosurg Psychiatry. 2016 Aug;87(8):821-30.
  8. Riku Y, Watanabe H, Yoshida M, Mimuro M, Iwasaki Y, Masuda M, Ishigaki S, Katsuno M, Sobue G. (2016) Marked Involvement of the Striatal Efferent System in TAR DNA-Binding Protein 43 kDa-Related Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis.J Neuropathol Exp Neurol[Epub ahead of print]
  9. Nakashima H, Ohkawara B, Ishigaki S, Fukudome T, Ito K, Tsushima M, Konishi H, Okuno T, Yoshimura T, Ito M, Masuda A, Sobue G, Kiyama H, Ishiguro N, Ohno K. (2016) R-spondin 2 promotes acetylcholine receptor clustering at the neuromuscular junction via Lgr5.Sci Rep 22, 28512.
  10. Watanabe, H., Atsuta, N., Hirakawa, A., Nakamura, R., Nakatochi, M., Ishigaki S., Iida, A., Ikegawa, S., Kubo, M., Yokoi, D., Watanabe, H., Ito, M., Katsuno, M., Izumi, Y., Morita, M., Kanai, K., Taniguchi, A., Aiba, I., Abe, K., Mizoguchi, K., Oda, M., Kano, O., Okamoto, K., Kuwabara, S., Hasegawa, K., Imai, T., Kawata, A., Aoki, M., Tsuji, S., Nakashima, K., Kaji, R., and Sobue, G. (2016). A rapid functional decline type of amyotrophic lateral sclerosis is linked to low expression of TTN.J Neurol Neurosurg Psychiatry 87, 851-858.　
  11. Xu Y, Halievski K, Henley C, Atchison WD, Katsuno M, Adachi H, Sobue G, Breedlove SM, Jordan CL. Defects in Neuromuscular Transmission May Underlie Motor Dysfunction in Spinal and Bulbar Muscular Atrophy.Neurosci. 2016 ;36(18):5094-106. doi: 10.1523/JNEUROSCI.3485-15.2016.
  12. Xu Y, Halievski K, Henley C, Atchison WD, Katsuno M, Adachi H, Sobue G, Breedlove SM, Jordan CL. Defects in Neuromuscular Transmission May Underlie Motor Dysfunction in Spinal and Bulbar Muscular Atrophy.J Neurosci. 2016 ;36(18):5094-106. doi: 10.1523/JNEUROSCI.3485-15.2016.
  13. Shahrizaila N, Sobue G, Kuwabara S, Kim SH, Birks C, Fan DS, Bae JS, Hu CJ, Gourie-Devi M, Noto Y, Shibuya K, Goh KJ, Kaji R, Tsai CP, Cui L, Talman P, Henderson RD, Vucic S, Kiernan MC. Amyotrophic lateral sclerosis and motor neuron syndromes in Asia.J Neurol Neurosurg Psychiatry. 2016.
  14. Yokoi D, Atsuta N, Watanabe H, Nakamura R, Hirakawa A, Ito M, Watanabe H, Katsuno M, Izumi Y, Morita M, Taniguchi A, Oda M, Abe K, Mizoguchi K, Kano O, Kuwabara S, Kaji R, Sobue G; JaCALS. Age of onset differentially influences the progression of regional dysfunction in sporadic amyotrophic lateral sclerosis.J Neurol. 2016;[Epub ahead of print]
  15. Ding Y, Adachi H, Katsuno M, Sahashi K, Kondo N, Iida M, Tohnai G, Nakatsuji H, Sobue G. BIIB021, a synthetic Hsp90 inhibitor, induces mutant ataxin-1 degradation through the activation of heat shock factor 1.Neuroscience. 2016;327:20-31.
  16. Bott LC, Badders NM, Chen KL, Harmison GG, Bautista E, Shih CC, Katsuno M, Sobue G, Taylor JP, Dantuma NP, Fischbeck KH, Rinaldi C. A small-molecule Nrf1and Nrf2 activator mitigates polyglutamine toxicity in spinal and bulbar muscular atrophy.Hum Mol Genet. 2016; pii: ddw073. [Epub ahead of print]
  17. Pourshafie N, Lee PR, Chen KL, Harmison GG, Bott LC, Katsuno M, Sobue G, Burnett BG, Fischbeck KH, Rinaldi C. MiR-298 counteracts mutant androgen receptor toxicity in spinal and bulbar muscular atrophy.Mol Ther. 2016;24(5):937-45.
  18. Kato T, Inui Y, Nakamura A, Ito K:Brain Fluorodeoxyglucose (FDG)PET in dementia Ageing Research Review, 2016; pii: S1568-1637(16)30011
  19. Nakashima T, Sugiura S, Naganawa S, Yasue M, Inui Y, Sakurai T, Uchida Y, Sone M, Teranishi M, Yoshida T, Ito K, Toba K. Cerumen impaction shown by brain magnetic resonance imaging in patients with cognitive impairment.Geriatr Gerontol Int. 2016; 16(3):392-5.
  20. Matsui T, Nakamura T, Utsumi A, Sasaki AT, Koike T, Yoshida Y, Harada T, Tanabe HC, Sadato N. (2016.4) The role of prosody and context in sarcasm comprehension: behavioral and fMRI evidence. Neuropsychologia, ePub ahead of print. DOI: 10.1016/j.neuropsychologia.2016.04.031.
  21. Yeung AWK, Tanabe HC, Suen JLK, Goto T (2016.4) Taste Intensity Modulates Effective Connectivity from the Insular Cortex to the Thalamus in Humans. NeuroImage, ePub ahead of print. DOI: 10.1016/j.neuroimage.2016.04.057
  22. Yoshihara K, Tanabe HC, Kawamichi H, Koike T, Yamazaki M, Sudo N, Sadato N (2016.4) “Neural correlates of fear-induced sympathetic response associated with the peripheral temperature change rate. NeuroImage, ePub ahead of print. DOI: 10.1016/j.neuroimage.2016.04.040
  23. Suzuki A, Ito Y, Kiyama S, Kunimi M, Ohira H, Kawaguchi J, Tanabe HC, Nakai T (2016.2) Involvement of the ventrolateral prefrontal cortex in learning others’ bad reputations and indelible disgust.Front. Hum. Neurosci.,10, 28. DOI: 10.3389/fnhum.2016.00028
  24. Nakamura R, Sone J, Atsuta N, Tohnai G, Watanabe H, Yokoi D, Nakatochi M, Watanabe H, Ito M, Senda J, Katsuno M, Tanaka F, Li Y, Izumi Y, Morita M, Taniguchi A, Kano O, Oda M, Kuwabara S, Abe K, Aiba I, Okamoto K, Mizoguchi K, Hasegawa K, Aoki M, Hattori N, Tsuji S, Nakashima K, Kaji R, Sobue G; Japanese consortium for amyotrophic lateral sclerosis research (JaCALS). Next-generation sequencing of 28 ALS-related genes in a Japanese ALS cohort.Neurobiol Aging. 2016;39:219.e1-8.
  25. Pourshafie N, Lee PR, Chen KL, Harmison GG, Bott LC, Katsuno M, Sobue G, Burnett BG, Fischbeck KH, Rinaldi C. MiR-298 counteracts mutant androgen receptor toxicity in spinal and bulbar muscular atrophy.Mol Ther. 2016;24(5):937-45.
  26. Bott LC, Badders NM, Chen KL, Harmison GG, Bautista E, Shih CC, Katsuno M, Sobue G, Taylor JP, Dantuma NP, Fischbeck KH, Rinaldi C. A small-molecule Nrf1and Nrf2 activator mitigates polyglutamine toxicity in spinal and bulbar muscular atrophy.Hum Mol Genet. 2016;pii: ddw073. [Epub ahead of print]
  27. Ding Y, Adachi H, Katsuno M, Sahashi K, Kondo N, Iida M, Tohnai G, Nakatsuji H, Sobue G. BIIB021, a synthetic Hsp90 inhibitor, induces mutant ataxin-1 degradation through the activation of heat shock factor 1.Neuroscience. 2016;327:20-31.
  28. Yokoi D, Atsuta N, Watanabe H, Nakamura R, Hirakawa A, Ito M, Watanabe H, Katsuno M, Izumi Y, Morita M, Taniguchi A, Oda M, Abe K, Mizoguchi K, Kano O, Kuwabara S, Kaji R, Sobue G; JaCALS. Age of onset differentially influences the progression of regional dysfunction in sporadic amyotrophic lateral sclerosis.J Neurol. 2016. [Epub ahead of print]
  29. Shahrizaila N, Sobue G, Kuwabara S, Kim SH, Birks C, Fan DS, Bae JS, Hu CJ, Gourie-Devi M, Noto Y, Shibuya K, Goh KJ, Kaji R, Tsai CP, Cui L, Talman P, Henderson RD, Vucic S, Kiernan MC. Amyotrophic lateral sclerosis and motor neuron syndromes in Asia.J Neurol Neurosurg Psychiatry. 2016.
  30. Xu Y, Halievski K, Henley C, Atchison WD, Katsuno M, Adachi H, Sobue G, Breedlove SM, Jordan CL. Defects in Neuromuscular Transmission May Underlie Motor Dysfunction in Spinal and Bulbar Muscular Atrophy.J Neurosci. 2016;36(18):5094-106. doi: 10.1523/JNEUROSCI.3485-15.2016.
  31. Kitaguchi N, Hasegawa M, Ito S, Kawaguchi K, Hiki Y, Nakai S, Suzuki N, Shimano Y, Ishida O, Kushimoto H, Kato M, Koide S, Kanayama K, Kato T, Ito K, Takahashi H, Mutoh T, Sugiyama S, Yuzawa Y. A prospective study on blood Aβ levels and the cognitive function of patients with hemodialysis: a potential therapeutic strategy for Alzheimer’s disease.Journal Neural Transm. 2015; 122(11):1593-607.
  32. Mishima A, Nihashi T, Ando Y, Kawai H, Kato T, Ito K, Terasawa T. Biomarkers Differentiating Dementia with Lewy Bodies from Other DementiasA Meta-Analysis.J Alzheimers Dis. 2015; 50(1):161-74.
  33. Ota K, Oishi N, Ito K, Fukuyama H; SEAD-J Study Group; Alzheimer’s Disease Neuroimaging Initiative. Effects of imaging modalities, brain atlases and feature selection on prediction of Alzheimer’s disease. J Neurosci Methods. 2015; 256:168-83.
  34. Onishi H, Hatazawa J, Nakagawara J, Ito K, Ha-Kawa SK, Masuda Y, Sugibayashi K, Takahashi M, Kikuchi K, Katsuta N: Impact of injected dose and acquisition time on a normal database by use of 3D-SSP in SPECT images: quantitative simulation studies.Radiol Phys Technol. 2015; 8(2):224-31.
  35. Hatano K, Sekimata K, Yamada T, Abe J, Ito K, Ogawa M, Magata Y, Toyohara J, Ishiwata K, Biggio G, Serra M, Laquintana V, Denora N, Latrofa A, Trapani G, Liso G, Suzuki H, Sawada M, Nomura M, Toyama H： Radiosynthesis and in vivo evaluation of two imidazopyridineacetamides, [11C]CB184 and [ 11C]CB190, as a PET tracer for 18 kDa translocator protein: direct comparison with [ 11C](R)-PK11195.Ann Nucl Med. 2015; 29(4):325-35.
  36. Ito K, Fukuyama H, Senda M, Ishii K, Maeda K, Yamamoto Y, Ouchi Y, Ishii K, Okumura A, Fujiwara K, Kato, T., Arahata Y, Washimi Y, Mitsuyama Y, Meguro K, Ikeda M, SEAD-J Study Group：Prediction of outcomes in MCI by using 18F-FDG-PET: A multicenter study.J Alzheimers Dis. 2015; 45(2):543-52.
  37. Kawakami S, Sato H, Sasaki AT, Tanabe HC, Yoshida Y, Saito M, Toyoda H, Sadato N, Kang Y (2016.1) The brain mechanisms underlying the perception of pungent taste of capsaicin and the subsequent autonomic responses.Front. Hum. Neurosci., 9, 720. DOI: 10.3389/fnhum.2015.00720
  38. Koike T, Tanabe HC, Okazaki S, Nakagawa E, Sasaki AT, Shimada K, Sugawara SK, Takahashi HK, Yoshihara K, Bosch-Bayard J, Sadato N (2016.1) Neural substrates of shared attention as a social memory: A hyperscanning functional magnetic resonance imaging study.NeuroImage, ePub ahead of print.DOI:10.1016/j.neuroimage.2015.09.076 *equally contributed
  39. Mizuno K, Tanaka M, Tanabe HC, Joudoi T, Kawatani J, Shigihara Y, Tomoda A, Miike T, Imai-Matsumura K, Sadato N, Watanabe Y (2015.9) Less efficient and costly processes of frontal cortex in childhood chronic fatigue syndrome. NeuroImage Clinical. 9, 355-368. DOI: 10.1016/j.nicl.2015.09.001
  40. Kawamichi H, Yoshihara K, Sugawara SK, Matsunaga M, Makita K, Hamano YH, Tanabe HC, Sadato N (2016.4) Helping behavior induced by empathetic concern attenuates anterior cingulate activation in response to others’ distress.Soc. Neurosci. 11(2):109-122. DOI: 10.1080/17470919.2015.1049709
  41. Shimada K, Hirotani M, Yokokawa H, Yoshida H, Makita K, Yamazaki-Murase M, Tanabe HC, Sadato N (2015.5) Fluency-dependent cortical activation associated with speech production and comprehension in second language learners.Neuroscience. 2015; 300, 474-492. DOI: 10.1016
  42. Matsuyoshi D, Morita T, Kochiyama T, Tanabe HC, Sadato N, Kakigi R (2015.3) Dissociable cortical pathways for qualitative and quantitative mechanisms in the face inversion effect. J. Neurosci 2015;35(10), 4268-4279. DOI: 10.1523/JNEUROSCI.3960-14.
  43. Ogihara N, Amano H, Kikuchi T, Morita Y, Hasegawa K, Kochiyama T, Tanabe HC (2015.1) Towards digital reconstruction of fossil crania and brain morphology.Anthropol. Sci. 2015;123(1), 57-68. DOI: 10.1537/ase.141109.
  44. Iida M, Katsuno M, Nakatsuji H, Adachi H, Kondo N, Miyazaki Y, Tohnai G, Ikenaka K, Watanabe H, Yamamoto M, Kishida K, Sobue G. Pioglitazone suppresses neuronal and muscular degeneration caused by polyglutamine-expanded androgen receptors.Hum Mol Genet. 2015;24(2):314-29.
  45. Watanabe H, Atsuta N, Nakamura R, Hirakawa A, Watanabe H, Ito M, Senda J, Katsuno M, Izumi Y, Morita M, Tomiyama H, Taniguchi A, Aiba I, Abe K, Mizoguchi K, Oda M, Kano O, Okamoto K, Kuwabara S, Hasegawa K, Imai T, Aoki M, Tsuji S, Nakano I, Kaji R, Sobue G. Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients.Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(3-4):230-6.
  46. Maesawa S, Bagarinao E, Fujii M, Futamura M, Motomura K, Watanabe H, Mori D, Sobue G, Wakabayashi T. Evaluation of resting state networks in patients with gliomas: connectivity changes in the unaffected side and its relation to cognitive function.PLoS One. 2015;10(2):e0118072.
  47. Endo F, Komine O, Fujimori-Tonou N, Katsuno M, Jin S, Watanabe S, Sobue G, Dezawa M, Wyss-Coray T, Yamanaka K. Astrocyte-derived TGF-β1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T cells.Cell Rep. 2015;11(4):592-604.
  48. Mitsui J, Matsukawa T, Sasaki H, (他23名), Watanabe H, Ito M, Sobue G, (他41名), Tsuji S. Variants associated with Gaucher disease in multiple system atrophy.Ann Clin Transl Neurol.2015 Apr;2(4):417-26.
  49. Udagawa T, Fujioka Y, Tanaka M, Honda D, Yokoi S, Riku Y, Ibi D, Nagai T, Yamada K, Watanabe H, Katsuno M, Inada T, Ohno K, Sokabe M, Okado H, Ishigaki S, Sobue G. FUS regulates AMPA receptor function and FTLD/ALS-associated behavior via GluA1 mRNA stabilization.Nat Commun. 2015;6:7098.
  50. Masuda A, Takeda J, Okuno T, Okamoto T, Ohkawara B, Ito M, Ishigaki S, Sobue G, Ohno K.Position-specific binding of FUS to nascent RNA regulates mRNA length.Genes Dev. 2015;29(10):1045-57
  51. Sahashi K, Katsuno M, Hung G, Adachi H, Kondo N, Nakatsuji H, Tohnai G, Iida M, Bennett CF, Sobue G. Silencing neuronal mutant androgen receptor in a mouse model of spinal and bulbar muscular atrophy.Hum Mol Genet. 2015;24(21):5985-94.
  52. Foyez T, Takeda-Uchimura Y, Ishigaki S, Narentuya, Zhang Z, Sobue G, Kadomatsu K, Uchimura K. Microglial keratan sulfate epitope elicits in central nervous tissues of transgenic model mice and patients with amyotrophic lateral sclerosis.Am J Pathol. 2015;185(11):3053-65.
  53. Picher-Martel V, Dutta K, Phaneuf D, Sobue G, Julien JP. Ubiquilin-2 drives NF-κB activity and cytosolic TDP-43 aggregation in neuronal cells.Mol Brain. 2015;8(1):71.
  54. Watanabe H, Atsuta N, Hirakawa A, Nakamura R, Nakatochi M, Ishigaki S, Iida A, Ikegawa S, Kubo M, Yokoi D, Watanabe H, Ito M, Katsuno M, Izumi Y, Morita M, Kanai K, Taniguchi A, Aiba I, Abe K, Mizoguchi K, Oda M, Kano O, Okamoto K, Kuwabara S, Hasegawa K, Imai T, Kawata A, Aoki M, Tsuji S, Nakashima K, Kaji R, Sobue G. A rapid functional decline type of amyotrophic lateral sclerosis is linked to low expression of TTN.J Neurol Neurosurg Psychiatry. 2016； pii: jnnp-2015-311541. doi: 10.1136/jnnp-2015-311541.
  55. Kaneko N, Nakamura A, Washimi Y, Kato T, Sakurai T, Arahata Y, Bundo M, Takeda A, Niida S, Ito K, Toba K, Tanaka K, and Yanagisawa K：Novel plasma biomarker surrogating cerebral amyloid deposition.Proc Jpn Acad Ser B. 2014; 90(9): 353-64.
  56. Ishii K, Ito K, Nakanishi A, Kitamura S, Terashima A： Computer-assisted system for diagnosing degenerative dementia using cerebral blood flow SPECT and 3D-SSP: a multicenter study.Jpn J Radiol. 2014; 32(7):383-90.
  57. Yamane T, Ikari Y, Nishio T, Ishii K, Ishii K, Kato T, Ito K,　D.H.S. Silverman, Senda M, Asada T, Arai H, Sugishita M, Iwatsubo T, and the J-ADNI Study Group. Visual-Statistical Interpretation of 18F-FDG-PET Images for Characteristic　Alzheimer Patterns in a Multicenter Study: Inter-Rater Concordance and Relationship to Automated Quantitative Evaluation.AJNR Am J Neuroradiol. 2014; 35(2):244-9.
  58. Ota K, Oishi N, Ito K, Fukuyama H; the SEAD-J Study Group.　A comparison of three brain atlases for MCI prediction.J Neurosci Methods. 2014; 221:139-50.
  59. Koike T, Tanabe HC, Sadato N (2015.1) “Hyperscanning neuroimaging technique to reveal the “two-in-one” system in social interactions.”Neurosci. Res., 90, 25-32. DOI: 10.1016/j.neures.2014.11.006
  60. Kawamichi H, Yoshihara K, Sasaki AT, Sugawara SK, Tanabe HC, Shinohara R, Sugisawa Y, Tokutake K, Mochizuki Y, Anme T, Sadato N (2014.9) “Perceiving active listening activates the reward system and improves the impression of relevant experiences.”,Soc. Neurosci. 2014;10, 16-26. DOI: 10.1080/17470919.2014.954732
  61. Sasai S, Homae F, Watanabe H, Sasaki AT, Tanabe HC, Sadato N, Taga G (2014.12) Frequency-specific network topologies in the resting human brain.Front. Hum. Neurosci. 2014;8, 1022. DOI: 10.3389/fnhum.
  62. Okamoto Y, Kitada R, Tanabe HC, Hayashi MJ, Kochiyama T, Munesue T, Ishitobi M, Saito DN, Yanaka HT, Omori M, Wada Y, Okazawa H, Sasaki AT, Morita T, Itakura S, Kosaka H, Sadato N (2014.10) Attenuation of the contingency detection effect in the extrastriate body area in autism spectrum disorder.Neurosci. Res. 2014;87,66-76. DOI: 10.1016/j.neures.
  63. Nakajima K, Minami T, Tanabe HC, Sadato N, Nakauchi S (2014.9) “Facial color processing in the face-selective regions: An fMRI study.”,Human Brain Mapping,　2014;35(9):4958-4964. DOI: 10.1002/hbm.22535
  64. Riku Y, Watanabe H, Yoshida M, Tatsumi S, Mimuro M, Iwasaki Y, Katsuno M, Iguchi Y, Masuda M, Senda J, Ishigaki S, Udagawa T, Sobue G. Lower motor neuron involvement in TAR DNA-binding protein of 43 kDa-related frontotemporal lobar degeneration and amyotrophic lateral sclerosis.JAMA Neurol. 2014;71(2):172-9.
  65. Ohkawa T, Satake S, Yokoi N, Miyazaki Y, Ohshita T, Sobue G, Takashima H, Watanabe O, Fukata Y, Fukata M. Identification and characterization of GABA(A) receptor autoantibodies in autoimmune encephalitis.J Neurosci. 2014;34(24):8151-63.
  66. Tohnai G, Adachi H, Katsuno M, Doi H, Matsumoto S, Kondo N, Miyazaki Y, Iida M, Nakatsuji H, Qiang Q, Ding Y, Watanabe H, Yamamoto M, Ohtsuka K, Sobue G. Paeoniflorin eliminates a mutant AR via NF-YA-dependent proteolysis in spinal and bulbar muscular atrophy.Hum Mol Genet. 2014;23(13):3552-65.
  67. Araki A, Katsuno M, Suzuki K, Banno H, Suga N, Hashizume A, Mano T, Hijikata Y, Nakatsuji H, Watanabe H, Yamamoto M, Makiyama T, Ohno S, Fukuyama M, Morimoto S, Horie M, Sobue G. Brugada syndrome in spinal and bulbar muscular atrophy.Neurology. 2014;82(20):1813-21.
  68. Kondo N, Katsuno M, Adachi H, Minamiyama M, Doi H, Matsumoto S, Miyazaki Y, Iida M, Tohnai G, Nakatsuji H, Ishigaki S, Fujioka Y, Watanabe H, Tanaka F, Nakai A, Sobue G. Heat shock factor-1 influences pathological lesion distribution of polyglutamine-induced neurodegeneration. Nat Commun. 2013;4:1405.
  69. Mitsui J, Matsukawa T, Ishiura H, （他20名）Watanabe H, Ito M, Sobue G, （他48名）: Mutations in COQ2 in familial and sporadic multiple-system atrophy. N Engl J Med. 2013;369:233-44.
  70. Miyazaki Y, Adachi H, Katsuno M, Minamiyama M, Jiang YM, Huang Z, Doi H, Matsumoto S, Kondo N, Iida M, Tohnai G, Tanaka F, Muramatsu S, Sobue G. Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2. Nat Med. 2012;18:1136-41.
  71. Minamiyama M, Katsuno M, Adachi H, Doi H, Kondo N, Iida M, Ishigaki S, Fujioka Y, Matsumoto S, Miyazaki Y, Tanaka F, Kurihara H, Sobue G. Naratriptan mitigates  CGRP1-associated motor neuron degeneration caused by an expanded polyglutamine repeat tract. Nat Med. 2012;18:1531-8.
  72. Katsuno M, Banno H, Suzuki K, Takeuchi Y, Kawashima M, (他23名) Sobue G: Japan SBMA Interventional Trial for TAP-144-SR (JASMITT) study group. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:875-84.
  73. Palazzolo I, Stack C, Kong L, Musaro A, Adachi H, Katsuno M, Sobue G, Taylor JP, Sumner CJ, Fischbeck KH, Pennuto M. Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron. 2009;63:316-28.
  74. Banno H, Katsuno M, Suzuki K, Takeuchi Y, Kawashima M, Suga N, Takamori M, Ito M, Nakamura T, Matsuo K, Yamada S, Oki Y, Adachi H, Minamiyama M, Waza M, Atsuta N, Watanabe H, Fujimoto Y, Nakashima T, Tanaka F, Doyu M, Sobue G. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol. 2009;65:140-50.
  75. Katsuno M, Adachi H, Sobue G. Getting a handle on Huntington’s disease: the case for cholesterol. Nat Med. 2009;15:253-4.
  76. Waza M, Adachi H, Katsuno M, Minamiyama M, Sang C, Tanaka F, Inukai A, Doyu M, Sobue G. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med. 2005;11:1088-95.
  77. Katsuno M, Sang C, Adachi H, Minamiyama M, Waza M, Tanaka F, Doyu M, Sobue G.  Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proc Natl Acad Sci U S A. 2005;102:16801-6.
  78. Katsuno M, Adachi H, Doyu M, Minamiyama M, Sang C, Kobayashi Y, Inukai A, Sobue G. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med. 2003;9:768-73.
  79. Katsuno M, Adachi H, Kume A, Li M, Nakagomi Y, Niwa H, Sang C, Kobayashi Y, Doyu M, Sobue G. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron. 2002;35:843-54.

A01-2

  1. Ng KP, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MS, Shin M, Guiot MC, Guo Q, Harada R, Comley RA, Massarweh G, Soucy JP, Okamura N, Gauthier S, Rosa-Neto P. Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain.Alzheimers Res Ther. 2017; 9: 25.
  2. Hsiao IT, Lin KJ, Huang KL, Huang CC, Chen HS, Wey SP, Yen TC, Okamura N, Hsu JL. Biodistribution and radiation dosimetry for the tau tracer 18F-THK-5351 in healthy human subjects.J Nucl Med. 2017(in press)
  3. de Leon MJ, Li Y, Okamura N, Tsui WH, Saint Louis LA, Glodzik L, Osorio RS, Fortea J, Butler T, Pirraglia E, Fossati S, Kim HJ, Carare RO, Nedergaard M, Benveniste H, Rusinek H. CSF clearance in Alzheimer Disease measured with dynamic PET.J Nucl Med. 2017 (in press)
  4. Okamura N, Yanai K. Brain imaging: Applications of tau PET imaging.Nat Rev Neurol.2017; 13: 197-198.
  5. Arakawa Y, Nai Y, Shidahara M, Furumoto S, Seki C, Okamura N, Tashiro M, Kudo Y, Yanai K, Gonda K, Watabe H. Prediction of the clinical standardized uptake value ratio in amyloid PET imaging using a biomathematical modeling approach towards the efficient development of a radioligand.J Nucl Med. 2017 (in press)
  6. Neelamegam R, Yokell DL, Rice PA, Furumoto S, Kudo Y, Okamura N, El Fakhri G. A report of the automated radiosynthesis of the tau PET radiopharmaceutical, [18F]-THK-5351.J Labelled Comp Radiopharm. 2017; 60: 140-146.
  7. Betthauser T, Lao PJ, Murali D, Barnhart TE, Furumoto S, Okamura N, Stone CK, Johnson SC, Christian BT. In vivo comparison of tau radioligands 18F-THK-5351 and 18F-THK-5317.J Nucl Med. (in press)
  8.  Ishiki A, Harada R, Okamura N, Tomita N, Rowe CC, Villemagne VL, Yanai K, Kudo Y, Arai H, Furumoto S, Tashiro M, Furukawa K. Tau imaging with [18F]THK-5351 in progressive supranuclear palsy.Eur J Neurol. 2017; 24: 130-136.
  9. Stepanov V, Svedberg M, Jia Z, Krasikova R, Lemoine L, Okamura N, Furumoto S, Mitsios N, Mulder J, Långström B, Nordberg A, Halldin C. Development of [11C]/[3H]THK-5351 – A potential novel carbon-11 tau imaging PET radioligand.Nucl Med Biol. 2016; 46: 50-53.
  10.  Kikuchi A, Okamura N, Hasegawa T, Harada R, Watanuki S, Funaki Y, Hiraoka K, Baba T, Sugeno N, Oshima R, Yoshida S, Kobayashi J, Ezura M, Kobayashi M, Tano O, Mugikura S, Iwata R, Ishiki A, Furukawa K, Arai H, Furumoto S, Tashiro M, Yanai K, Kudo Y, Takeda A, Aoki M. In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET.Neurology. 2016; 87: 2309-2316.
  11. Schönecker S, Brendel M, Huber M, Vollmar C, Huppertz HJ, Teipel S, Okamura N, Levin J, Rominger A, Danek A. Applied multimodal diagnostics in a case of presenile dementia.BMC Neurol. 2016; 16: 131.
  12.  Villemagne VL, Okamura N, Rowe CC. Untangling tau imaging.Alzheimers Dement Amst). 2016; 4: 39-42.
  13. Harada R, Furumoto S, Tago T, Furukawa K, Ishiki A, Tomita N, Iwata R, Tashiro M, Arai H, Yanai K, Kudo Y, Okamura N. Characterization of the radiolabeled metabolite of tau PET tracer 18F-THK5351.Eur J Nucl Med Mol Imaging. 2016; 43: 2211-2218.
  14. Lockhart SN, Baker SL, Okamura N, Furukawa K, Ishiki A, Furumoto S, Tashiro M, Yanai K, Arai H, Kudo Y, Harada R, Tomita N, Hiraoka K, Watanuki S, Jagust WJ. Dynamic PET measures of tau accumulation in cognitively normal older adults and Alzheimer’s disease patients measured using [18F]　THK-5351.PLoS One. 2016; 11: e0158460.
  15. Furumoto S, Tago T, Harada R, Kudo Y, Okamura N. 18F-Labeled 2-arylquinoline derivatives for tau imaging: chemical, radiochemical, biological and clinical features.Curr Alzheimer Res. 2017; 14: 178-185.
  16. Shimozawa A, Ono M, Takahara D, Tarutani A, Imura S, Masuda-Suzukake M, Higuchi M, Yanai K, Hisanaga SI, Hasegawa M. Propagation of pathological α-synuclein in marmoset brain.Acta Neuropathol Commun. 2017 Feb 2;　5(1):12.
  17. Arakawa Y, Nai Y, Shidahara M, Furumoto S, Seki C, Okamura N, Tashiro M, Kudo Y, Yanai K, Gonda K, Watabe H. Prediction of the clinical standardized uptake value ratio in amyloid PET imaging using a bio-mathematical modeling approach towards the efficient development of a radioligand.J Nucl Med. 2017 Jan 6. In press
  18. Brendel M, Jaworska A, Probst F, Overhoff F, Korzhova V, Lindner S, Carlsen J, Bartenstein P, Harada R, Kudo Y, Haass C, van Leuven F, Okamura N, Herms J, Rominger A. Small-animal PET imaging of tau pathology with 18F-THK5117 in 2 transgenic mouse models.J Nucl Med. 2016 57: 792-798.
  19. Okamura N, Harada R, Furukawa K, Furumoto S, Tago T, Yanai K, Arai H, Kudo Y. Advances in the Development of Tau PET Radiotracers and Their Clinical Applications.Ageing Res Rev 2016 (in press)
  20. Furukawa K, Ishiki A, Tomita N, Onaka Y, Saito H, Nakamichi T, Hara K, Kusano Y, Ebara M, Arata Y, Sakota M, Miyazawa I, Totsune T, Okinaga S, Okamura N, Kudo Y, Arai H. Introduction and overview of the special issue “Brain imaging and aging”: The new era of neuroimaging in aging research.Ageing Res Rev. 2016 (in press)
  21. Harada R, Okamura N, Furumoto S, Tago T, Yanai K, Arai H, Kudo Y. Characteristics of tau and its ligands in PET imaging.Biomolecules. 2016; 6: 7.
  22. Harada R, Furumoto S, Yoshikawa T, Ishikawa Y, Shibuya K, Okamura N, Ishiwata K, Iwata R, Yanai K. Synthesis and characterization of 18F-interleukin-8 using a cell-free translation system and 18F-fluoro-L-proline.J Nucl Med. 2016 57: 634-639.
  23. Tago T, Furumoto S, Okamura N, Harada R, Adachi H, Ishikawa Y, Yanai K, Iwata R, Kudo Y. Structure-activity relationship of 2-Arylquinolines as PET imaging tracers for tau pathology in Alzheimer’s disease.J Nucl Med. 2016; 57: 608-614.
  24. Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, Tago T, Hiraoka K, Watanuki S, Shidahara M, Miyake M, Ishikawa Y, Matsuda R, Inami A, Yoshikawa T, Funaki Y, Iwata R, Tashiro M, Yanai K, Arai H, Kudo Y. 18F-THK5351: A novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer’s disease.J Nucl Med. 2016; 57: 208-214.
  25. Tago T, Furumoto S, Okamura N, Harada R, Adachi H, Ishikawa Y, Yanai K, Iwata R, Kudo Y. Preclinical evaluation of [18F]THK-5105 enantiomers: Effects of chirality on its effectiveness as a tau imaging radiotracer.Mol Imaging Biol. 2016; 18: 258-266.
  26. Villemagne VL, Okamura N. Tau imaging in the study of ageing, Alzheimer’s disease, and other neurodegenerative conditions.Curr Opin Neurobiol. 2016; 36: 43-51.
  27. Ishiki A, Okamura N, Furukawa K, Furumoto S, Harada R, Tomita N, Hiraoka K, Watanuki S, Ishikawa Y, Tago T, Funaki Y, Iwata R, Tashiro M, Yanai K, Kudo Y, Arai H. Longitudinal assessment of tau pathology in patients with Alzheimer’s disease using [18F]THK-5117 positron emission tomography.PLoS One. 2015; 10: e0140311.
  28. Hiraoka K, Narita W, Kikuchi H, Baba T, Kanno S, Iizuka O, Tashiro M, Furumoto S, Okamura N, Furukawa K, Arai H, Iwata R, Mori E, Yanai K. Amyloid deposits and response to shunt surgery in idiopathic normal-pressure hydrocephalus.J Neurol Sci. 2015; 356: 124-128.
  29. Shidahara M, Watabe H, Tashiro M, Okamura N, Furumoto S, Watanuki S, Furukawa K, Arakawa Y, Funaki Y, Iwata R, Gonda K, Kudo Y, Arai H, Ishiwata K, Yanai K. Quantitative kinetic analysis of PET amyloid imaging agents [11C]BF227 and [18F]FACT in human brain.Nucl Med Biol. 2015;42: 734-744.
  30. Lemoine L, Saint-Aubert L, Marutle A, Antoni G, Eriksson JP, Ghetti B, Okamura N, Nennesmo I, Gillberg PG, Nordberg A. Visualization of regional tau deposits using 3H-THK5117 in Alzheimer brain tissue.Acta Neuropathol Commun. 2015; 3: 40.
  31. Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, Hiraoka K, Watanuki S, Shidahara M, Miyake M, Ishikawa Y, Matsuda R, Inami A, Yoshikawa T, Tago T, Funaki Y, Iwata R, Tashiro M, Yanai K, Arai H, Kudo Y. [18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease.Eur J Nucl Med Mol Imaging. 2015; 42: 1052-1061.
  32. Li Y, Tsui W, Rusinek H, Butler T, Mosconi L, Pirraglia E, Mozley D, Vallabhajosula S, Harada R, Furumoto S, Furukawa K, Arai H, Kudo Y, Okamura N, de Leon MJ. Cortical laminar binding of PET amyloid and tau tracers in Alzheimer disease. J Nucl Med. 2015;56: 270-273.
  33. Zwan MD, Okamura N, Fodero-Tavoletti MT, Furumoto S, Masters CL, Rowe CC, Villemagne VL. Voyage au bout de la nuit: Aβ and tau imaging in dementias. Q J Nucl Med Mol Imaging. 2014;58: 398-412.
  34. Okamura N, Harada R, Furumoto S, Arai H, Yanai K, Kudo Y. Tau PET imaging in Alzheimer’s disease. Curr Neurol Neurosci Rep . 2014;14: 500.
  35. Arai A, Kaneta T, Okamura N, Tashiro M, Iwata R, Takanami K, Fukuda H, Takahashi S, Yanai K, Kudo Y, Arai H. Pitfalls of voxel-based amyloid PET analyses for diagnosis of Alzheimer’s disease: artifacts due to non-specific uptake in the white matter and the skull.Tohoku J Exp Med. 2014;234: 175-181.
  36. Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, Pejoska S, Kudo Y, Masters CL, Yanai K, Rowe CC, Villemagne VL. Noninvasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET. Brain. 2014;137:1762-71.
  37. Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, Mulligan RS, Villemagne VL, Akatsu H, Yamamoto T, Arai H, Iwata R, Yanai K, Kudo Y. Novel 18F-labeled arylquinoline derivatives for non-invasive imaging of tau pathology in Alzheimer’s disease. J Nucl Med. 2013;54:1420-7.
  38. Furumoto S, Okamura N, Furukawa K, Tashiro M, Ishikawa Y, Sugi K, Tomita N, Waragai M, Harada R, Tago T, Iwata R, Yanai K, Arai H, Kudo Y. A 18F-Labeled BF-227 Derivative as a Potential Radioligand for Imaging Dense Amyloid Plaques by Positron Emission Tomography. Mol Imaging Biol. 2013;15:497-506.
  39. Furukawa K, Ikeda S, Okamura N, Tashiro M, Tomita N, Furumoto S, Iwata R, Yanai K, Kudo Y, Arai H. Cardiac positron-emission tomography images with an amyloid-specific tracer in familial transthyretin-related systemic amyloidosis. Circulation. 2013;125:556-7.
  40. Kasuya M, Meguro K, Okamura N, Funaki Y, Ishikawa H, Tanaka N, Iwata R, Yanai K. Greater responsiveness to donepezil in Alzheimer patients with higher levels of acetylcholinesterase based on attention task scores and a donepezil PET study. Alzheimer Dis Assoc Disord. 2012;26:113-8.
  41. Fodero-Tavoletti MT, Okamura N, Furumoto S, Mulligan RS, Connor A, McLean CA, Cao D, Rigopoulos A, O’Keefe G, Gong S, Adlard PA, Barnham KJ, Rowe CC, Masters CL, Kudo Y, Cappai R, Yanai K, Villemagne VL. [18F]-THK523, a novel in vivo tau imaging ligand for Alzheimer’s disease. Brain. 2011;134: 1089-100.
  42. Kikuchi A, Takeda A, Okamura N, Tashiro M, Hasegawa T, Furumoto S, Kobayashi M, Sugeno N, Baba T, Miki Y, Mori F, Wakabayashi K, Funaki Y, Fukuda H, Arai H, Kudo Y, Yanai K, Itoyama Y. In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2 -(fluoro)ethoxy] benzoxazole positron emission tomography in multiple system atrophy. Brain. 2010;133:1772-8.
  43. Okamura N, Shiga Y, Furumoto S, Tashiro M, Tsuboi Y, Furukawa K, Yanai K, Iwata R, Arai H, Kudo Y, Itoyama Y, Doh-ura K. In vivo detection of prion amyloid plaques using [11C]BF-227 PET. Eur J Nucl Med Mol Imaging. 2010;37:934-41.
  44. Okamura N, Funaki Y, Tashiro M, Kato M, Ishikawa Y, Maruyama M, Ishikawa H, Meguro K, Iwata R, Yanai K. In vivo visualization of donepezil binding in the brain of patients with Alzheimer’s disease. Br J Clin Pharmacol. 2008;65:472-9.
  45. Okamura N, Suemoto T, Furumoto S, Suzuki M, Shimadzu H, Akatsu H, Yamamoto T, Fujiwara H, Nemoto M, Maruyama M, Arai H, Yanai K, Sawada T, Kudo Y. Quinoline and Benzimidazole Derivatives: Candidate Probes for In Vivo Imaging of Tau Pathology in Alzheimer’s Disease. J Neurosci. 2005;25:10857-62.

A01-公募班員

  1. Sano K, Ohashi M, Kanazaki K, Makino A, Ding N, Deguchi J, Kanada Y, Ono M, Saji, H.Indocyanine. green- labeled polysarcosine for in vivo photoacoustic tumor imaging.Bioconjugate Chem, in press
  2. Kimura H, Matsuda H, Ogawa Y, Fujimoto H, Toyoda K, Fujita N, Arimitsu K, Hamamatsu K, Yagi Y, Ono M, Inagaki N, Saji H.Development of 111In-labeled Exendin(9-39) Derivatives for Single-Photon Emission Computed Tomography Imaging of Insulinoma Bioorg. Med.Chem., 25(4), 1406-1412 (2017)
  3. Iikuni S, Ono M, Watanabe H, Yoshimura M, Ishibashi-Ueda H, Ihara M, Saji H. Novel Bivalent 99mTc-Complex with N-Methyl-Substituted Hydroxamamide as Probe for Imaging of Cerebral Amyloid Angiopathy. PLoS ONE, 11(9) e0163969 (2016)
  4. Ono M, Watanabe H, Kitada A, Matsumura K, Ihara M, Saji H. Highly Selective Tau-SPECT Imaging Probes for Detection of Neurofibrillary Tangles in Alzheimer’s Disease Sci. Rep. 6 34197 (2016)
  5. Kimura H, Yagi Y, Arimitsu K, Maeda K, Ikejiri K, Takano J, Kusuhara H, Kagawa S, Ono M, Sugiyama Y, Saji H. Radiosynthesis of Novel Pitavastatin Derivative ([18F]PTV-F1) as a Tracer for hepatic OATP Using a One-Pot Synthetic Procedure J. Labelled Compd.Radiopharm . 59(13) 565-575 (2016)
  6. Kimura H, Tomatsu K, Saiki H, Arimitsu K, Ono M, Kawashima H, Iwata R, Nakanishi H, Ozeki E, Kuge Y, Saji H. Continuous-flow synthesis of N-succinimidyl 4-[18F] fluorobenzoate using a single microfluidic chip. PLoS ONE11(7) e0159303 (2016)
  7. Harada N, Kimura H, Onoe S, Watanabe H, Matsuoka D, Arimitsu K, Ono M, Saji H. Synthesis and Biological Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for Positron Emission Tomography of Prostate Cancer. J. Nucl. Med. 57(12) 1978-1984 (2016)
  8. Ding N, Sano K, Kanazaki K, Ohashi M, Deguchi J, Kanada Y, Ono M, Saji H. In vivo HER2-Targeted Magnetic Resonance Tumor Imaging Using Iron Oxide Nanoparticles Conjugated with Anti-HER2 Fragment Antibody Mol.Imaging Biol. 18(6) 870-876 (2016)
  9. Yoshimura M, Ono M, Watanabe H, Kimura H, Saji H. Development of 99mTc-labeled Pyridyl Benzofuran Derivatives to Detect Pancreatic Amylin in Islet Amyloid Model Mice.Bioconjugate Chem. 27(6) 1532-1539 (2016)
  10. Watanabe H, Kawasaki A, Sano K, Ono M, Saji H. Synthesis and evaluation of copper-64 labeled benzofuran derivatives targeting β-amyloid aggregates Bioorg.Med. Chem.24(16) 3618-3623 (2016)
  11. Iikuni S, Ono M, Watanabe H, Matsumura K, Yoshimura M, Kimura H, Ishibashi-Ueda H, Okamoto Y, Ihara M, Saji H. Imaging of Cerebral Amyloid Angiopathy with Bivalent 99mTc-Hydroxamamide Complexes.Sci Rep. 6 25990 (2016)
  12. Ono M, Doi Y, Watanabe H, Ihara M, Ozaki A, Saji H. Structure-Activity Relationships of Radioiodinated Diphenyl Derivatives with Different Conjugated Double Bonds as Ligands for α-Synuclein Aggregates.RSC Adv. 6(50) 44305-44312 (2016)
  13. Ono M, Kitada A, Watanabe H, Miyazaki A, Kimura H, Saji H. Synthesis and Preliminary Characterization of Radioiodinated Benzofuran-3-yl-(indol-3-yl)maleimide Derivatives as Potential SPECT Imaging Probes for the Detection of Glycogen Synthase Kinase-3β (GSK-3β) in the Brain J. Labelled Comp.Radiopharm. 59(8) 317-321 (2016)
  14. Kimura H, Sampei S, Matsuoka D, Harada N, Watanabe H, Arimitsu K, Ono M, Saj H. Development of 99mTc-labeled Asymmetric Urea Derivatives that Target Prostate-Specific Membrane Antigen for Single-photon Emission Computed Tomography Imaging Bioorg.Med. Chem. 24(10) 2251-2256 (2016)
  15. Kanazaki K, Sano K, Makino A, Yamauchi F, Takahashi A, Homma T, Ono M, Saji H. Feasibility of poly(ethylene glycol) derivatives as diagnostic drug carriers for tumor imaging.J. Control. Release 226 115-123 (2016)
  16. Makino A, Arai T, Hirata M, Ono M, Ohmomo Y, Saji H. Development of novel PET probes targeting phosphatidylinositol 3-kinase (PI3K) in tumors Nucl.Med. Biol. 43(1) 101-107 (2016)
  17. Nakamura K., Groiss S.J. Hamada M., Enomoto H., Kadowaki S., Abe M., Murakami T., Wiratman W., Chang F., Kobayashi S., Hanajima R., Terao Y., Ugawa Y. Variability in response to quadripulse stimulation of the motor cortex.Brain Stimulation2016; 9: 859-866.
  18. Murakami T., Yoshida K., Segawa M., Yoshihara A., Hoshi A., Nakamura K., Ichikawa M., Suzuki O., Yokoyama Y., Toyoshima Y., Sugiura Y., Ito H., Saito K., Hashimoto Y., Kakita A., Takahashi H., Ugawa Y. A case of lymphomatosis cerebri mimicking inflammatory diseases.BMC Neurology2016; doi: 10.1186/s12883-016-0655-7.
  19. Kadowaki S., Enomoto H., Murakami T., Nakatani-Enomoto S., Kobayashi S., Ugawa Y. Influence of phasic muscle contraction upon the quadripulse stimulation (QPS) aftereffects.Clinical Neurophysiology/2016; 127: 1568-1573.
  20. Kotaro Mizuta, Tsugumi Fujita, Hiroki Yamagata, Eiichi Kumamoto. Bisphenol A inhibits compound action potentials in the frog sciatic nerve in a manner independent of estrogen receptors.Biochem Biophys Rep, (10) 145-151, 2017
領域事務局： 名古屋大学大学院医学系研究科 3号館908号室内
TEL: 052-744-2026 FAX:052-731-8131
E-mail:

Copyright © 文部科学省科学研究費補助金新学術領域研究 脳タンパク質老化と認知症制御